FDA Approves Nucala As Treatment For Severe Asthma

The U.S. Food and Drug Administration approved GlaxoSmithKline's first anti-asthma drug that inhibits interleukin-5. Nucala has shown significant reduction in asthma attacks among patients in their clinical trial.